December 07, 2020 08:55 ET | Source: Sarepta Therapeutics, Inc.
-- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation --
-- At a total dose exposure approximately 10x lower than eteplirsen, SRP-5051 at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping, and greater dystrophin production with no negative renal or other laboratory findings --
-- These are the first clinical results from the Companys peptide phosphorodiamidate morpholino oligomer (PPMO) technology, its next-generation chemistry platform --
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced results from the ongoing MOMENTUM study (Study 5051-201), a global Phase 2 clinical trial, of SRP-5051, its next-generation treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. This is the first clinical data from SRP-5051, an investigational treatment that uses Sareptas peptide phosphorodiamidate morpholino oligomer (PPMO) technology. PPMO technology includes a proprietary cell-penetrating peptide that is conjugated to Sareptas PMO backbone with the goal of increasing cellular uptake of drug in the muscle tissue.
Results from Part A of the multi-ascending dose MOMENTUM study found consistently higher tissue exposure, exon-skipping and dystrophin production in patients taking a monthly dose of SRP-5051 compared to baseline. SRP-5051 was generally well-tolerated across all doses studied, with no clinical or laboratory findings reported. The results support continued dose escalation of SRP-5051 and further clinical development.
Sareptas PMO RNA technology is a vital platform on which we design therapies to treat those with Duchenne muscular dystrophy. Our next-generation PPMO technology is designed to increase cell penetration with the goal of offering significantly improved efficacy with more convenient dosing in Duchenne patients amenable to exon skipping, said Doug Ingram, president and chief executive officer, Sarepta. While patient numbers in each dose arm are small, the higher tissue concentration, exon skipping and dystrophin production in the 20 mg/kg dosing group were observed at an early 12-week timepoint and with far less cumulative drug exposure when compared to our current PMO technology. We know from our experience with PMOs that exon-skipping and dystrophin increase over time, and these results along with our preclinical experience, give us confidence as we dose escalate and continue to advance our PPMO exon-skipping therapies for Duchenne, including another five potential therapies that have already been designed, and explore the utility of the PPMO RNA platform for new disease indications.
When compared to a control group of Duchenne patients from the PROMOVI study who received biopsies at 24 weeks after taking a weekly 30 mg/kg dose of eteplirsen, once-monthly dosing of SRP-5051 resulted in higher muscle concentration, increased exon-skipping and dystrophin at 12 weeks. A dose-dependent increase in exon-skipping and dystrophin was observed, with patients in the 20 mg/kg dose group of SRP-5051 seeing a 1.6-fold increase in exon skipping (n=4) and a 5-fold increase in the % of normal dystrophin (n=2) when compared to the group taking eteplirsenat 24 weeks.
The incidence of adverse events in the MOMENTUM study was similar across all dosed cohorts and does not suggest dose dependency. One treatment-emergent event, unrelated to study drug, occurred in the 4 mg/kg dose group. No clinical or laboratory findings were observed. Full results will be presented at a future medical meeting.
About MOMENTUM (SRP-5051-201) MOMENTUM is a multi-arm, ascending dose study designed to identify the maximum tolerated dose of SRP-5051. Informed by Study 5051-101, a single-ascending dose study of SRP-5051, patients in the MOMENTUM study will receive monthly intravenous (IV) infusions of SRP-5051, starting at 4 mg/kg and ascending to 40 mg/kg. The study will enroll up to 24 patients, both ambulant and non-ambulant, between the ages of 7 to 21 at sites in the U.S., Canada, Australia and European Union. The primary endpoint is safety, and secondary and exploratory endpoints include exon-skipping, dystrophin expression and tissue concentration. All patients will undergo a muscle biopsy at baseline and 12 weeks in Part A and at baseline and 24 weeks in Part B. More information can be found on http://www.clinicaltrials.gov.
About SRP-5051 SRP-5051 uses Sareptas PPMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein. PPMO is Sareptas next-generation chemistry platform designed around a proprietary cell-penetrating peptide conjugated to the PMO backbone, with the goal of increasing tissue penetration, increasing exon skipping and significantly increasing dystrophin production. Around 13% of DMD patients have mutations which make them amenable to skipping exon 51. If successful, the PPMO offers the potential for improved efficacy and less frequent dosing for patients.
About Duchenne Muscular Dystrophy DMD is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 - 5,000 male births worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs spreads to the arms, neck and other areas of the body. The condition is universally fatal, and death usually occurs before the age of 30 due to respiratory or cardiac failure.
About EXONDYS 51 EXONDYS 51 (eteplirsen) uses Sareptas proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin pre-mRNA, resulting in skipping of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in some patients treated with EXONDYS 51. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.
EXONDYS 51 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Important Safety Information About EXONDYS 51 Hypersensitivity reactions, including rash and urticaria, pyrexia, flushing, cough, dyspnea, bronchospasm, and hypotension, have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.
Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 mg or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.
In the 88 patients who received 30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in 10% of patients and occurred more frequently than on the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.
For further information, please see the fullPrescribing Information.
AboutSarepta Therapeutics At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Forward-Looking Statements This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the potential benefits of PPMO, including increasing cellular uptake of drug in the muscle tissue and offering significantly improved efficacy with less frequent dosing; our plan to continue to dose escalate and advance our PPMO exon-skipping therapies for Duchenne, including another five potential therapies that have already been designed, and to explore the utility of the PPMO RNA platform for new disease indications; and potential market opportunities.
These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Known risk factors include, among others: success in preclinical trials and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful; the data presented in this release may not be consistent with the final data set and analysis thereof or result in a safe or effective treatment benefit; different methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials of our product candidates are positive, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities; if the actual number of patients suffering from DMD is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans and goals, including meeting our expected or planned regulatory milestones and timelines, clinical development plans, and bringing our product candidates to market, due to a variety of reasons, some of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the COVID-19 pandemic; and even if Sareptas programs result in new commercialized products, Sarepta may not achieve the expected revenues from the sale of such products; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Companys business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com
Media: Tracy Sorrentino, 617-301-8566,tsorrentino@sarepta.com
Follow this link:
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular...
- Muscular .Dystrophy -Successful-treatment by acupressure , Ayurveda, Yoga [Last Updated On: May 10th, 2011] [Originally Added On: May 10th, 2011]
- Muscular Dystrophy Treatment - Todd Harrison Improving Balance [Last Updated On: May 16th, 2011] [Originally Added On: May 16th, 2011]
- Oculopharyngeal Muscular Dystrophy (OPMD): Exploring Causes and Treatment [Last Updated On: May 20th, 2011] [Originally Added On: May 20th, 2011]
- Muscular Dystrophy Treatment - Todd Harrison holding body weight [Last Updated On: May 21st, 2011] [Originally Added On: May 21st, 2011]
- David G VECTTOR Muscular Dystrophy Treatment double arm strength month 6 [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- David Gould Becker Muscular Dystrophy VECTTOR Treatment [Last Updated On: June 2nd, 2011] [Originally Added On: June 2nd, 2011]
- Muscular Dystrophy Halo [Last Updated On: June 3rd, 2011] [Originally Added On: June 3rd, 2011]
- Muscular Dystrophy VECTTOR Treatment Documentary - Todd's 6 Month Journey [Last Updated On: June 7th, 2011] [Originally Added On: June 7th, 2011]
- Muscular Dystrophy Treatment Results - David Gould - New Footage [Last Updated On: June 8th, 2011] [Originally Added On: June 8th, 2011]
- Muscular Dystrophy - Rewriting History with VECTTOR [Last Updated On: June 10th, 2011] [Originally Added On: June 10th, 2011]
- Muscular Dystrophy - David Gould 5 month VECTTOR treatment for BMD [Last Updated On: June 12th, 2011] [Originally Added On: June 12th, 2011]
- Duchenne's Muscular Dystrophy Stem Cell Treatment - Reelabs India [Last Updated On: June 14th, 2011] [Originally Added On: June 14th, 2011]
- Muscular Dystrophy VECTTOR Treatment - Todd Harrison/Luau Presentation [Last Updated On: June 16th, 2011] [Originally Added On: June 16th, 2011]
- Dr. William Rader - Muscular Dystrophy Breakthrough [Last Updated On: June 16th, 2011] [Originally Added On: June 16th, 2011]
- Muscular Dystrophy patient at Xcell-center - Nabeel Mohamed Abdulhusain, 46 years [Last Updated On: June 17th, 2011] [Originally Added On: June 17th, 2011]
- Charlie's Story: Duchenne Muscular Dystrophy Part 4 [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- Muscular Dystrophy VECTTOR Treatment - David Gould/Luau Presentation [Last Updated On: July 19th, 2011] [Originally Added On: July 19th, 2011]
- Testimonial 4 of Muscular Dystrophy after Stem Cell Therapy [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- Drug Combo Dynamic in Muscular Dystrophy [Last Updated On: August 9th, 2011] [Originally Added On: August 9th, 2011]
- Testimonial for Fetal Stem Cell Treatment of Duchenne Muscular Dystrophy [Last Updated On: August 25th, 2011] [Originally Added On: August 25th, 2011]
- Improvement seen in Duchenne Muscular Dystrophy after Stem Cell Therapy [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Muscular Dystrophy STS/VECTTOR treatment results [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Muscular Dystrophy VECTTOR Treatment Documentary - Todd's One Year Journey [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Muscular Dystrophy Treatment Day 18 - Todd Harrison's Improvement [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Wang Yisheng - Muscular Dystrophy Adult Stem Cell Patient [Last Updated On: October 9th, 2011] [Originally Added On: October 9th, 2011]
- Becker Muscular Dystrophy Miracle TREATMENT [Last Updated On: October 11th, 2011] [Originally Added On: October 11th, 2011]
- Muscular dystrophy patient_Kleber_Brazil.wmv [Last Updated On: October 12th, 2011] [Originally Added On: October 12th, 2011]
- Testimonial 1 of Muscular Dystrophy after Stem Cell Therapy - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Becker Muscular Dystrophy STS Treatment - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Potential Stem Cell treatment of Duchenne Muscular Dystrophy - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Muscular Dystrophy treated by Dr Rajesh Shah at Life Force - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- Defying Muscular Dystrophy - I Made It - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- Becker Muscular Dystrophy AMAZING treatment results - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- First targeted treatment success for Duchenne muscular dystrophy - Video [Last Updated On: November 6th, 2011] [Originally Added On: November 6th, 2011]
- 125 Days of VECTTOR Treatment Progress [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- Becker Muscular Dystrophy WALKING ABILITY IMPROVED - Video [Last Updated On: November 25th, 2011] [Originally Added On: November 25th, 2011]
- PT Muscular Dystrophy Treatment Results - Video [Last Updated On: December 5th, 2011] [Originally Added On: December 5th, 2011]
- Duchenne Muscular Dystrophy Treated by Cellmedicine - Video [Last Updated On: January 8th, 2012] [Originally Added On: January 8th, 2012]
- muscular DYSTROPHY treatment IN HOMEOPATH.mp4 - Video [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Giulio's strategy is to cure dystrophy with stem cell treatment - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Parent Project Muscular Dystrophy is a Featured Nonprofit Selected by Webkinz(TM) Foundation [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- MDA Awards More Than $12 Million in Grants to Advance Neuromuscular Disease Research [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- "For treatment we will have in the future" - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Renowned Pediatric Cardiology Physician-Scientist Linda Cripe Joins Nationwide Children's Hospital [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- JumpStart Invests $250,000 in Milo Biotechnology [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- When nerve meets muscle, biglycan seals the deal [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Medical clinics offer help for Big Island children [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- Dateline Long Beach: The Aquatic Center brings swim therapy to disabled [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- Parent Project Muscular Dystrophy Awards $500,000 to Tivorsan Pharmaceuticals [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne ... [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Ligand Licenses DARA Program to Retrophin [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- AVI BioPharma Regains NASDAQ Compliance [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- Scientists create potent molecules aimed at treating muscular dystrophy [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Corporate Update Conference Call [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- Pembroke's Christine McSherry is an 'Inspirational Woman' [Last Updated On: February 25th, 2012] [Originally Added On: February 25th, 2012]
- The Rare Clinical Diseases Research Network [Last Updated On: February 25th, 2012] [Originally Added On: February 25th, 2012]
- A Solution for Duchenne Muscular Dystrophy? - Research Summary [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- A Solution for Duchenne Muscular Dystrophy? -- In Depth Doctor's Interview [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- Antisense oligonucleotides make sense in myotonic dystrophy [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- A life of dependence [Last Updated On: February 29th, 2012] [Originally Added On: February 29th, 2012]
- Nationwide Children's Hospital neuromuscular disorder podcasts now available on iTunes [Last Updated On: March 2nd, 2012] [Originally Added On: March 2nd, 2012]
- Next-generation DNA sequencing to improve diagnosis for muscular dystrophy [Last Updated On: March 6th, 2012] [Originally Added On: March 6th, 2012]
- The Dire Limits of Health Care [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- AVI BioPharma Announces Late-Breaker Oral Presentation of Phase IIb DMD Study at 2012 AAN Annual Meeting in April [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- Cataracts affect millions of people around the globe, and for many of us they will be a normal part of our aging ... [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- Your Health: Duchenne's Muscular Dystrophy [Last Updated On: March 16th, 2012] [Originally Added On: March 16th, 2012]
- Newborn Screening for Duchenne Muscular Dystrophy Shows Promise as an International Model [Last Updated On: March 20th, 2012] [Originally Added On: March 20th, 2012]
- Newborn screening for DMD shows promise as an international model [Last Updated On: March 20th, 2012] [Originally Added On: March 20th, 2012]
- Rhenovia launches drug discovery for Huntington's disease [Last Updated On: March 20th, 2012] [Originally Added On: March 20th, 2012]
- Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 [Last Updated On: March 21st, 2012] [Originally Added On: March 21st, 2012]
- Invasive treatment strategy may increase survival for patients with certain neuromuscular disorder [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- Parent Project Muscular Dystrophy Endorses FAST Act Legislation to Expedite FDA Review of Life-Saving Therapies [Last Updated On: March 29th, 2012] [Originally Added On: March 29th, 2012]
- AVI BioPharma Announces Conference Call and Webcast on Monday, April 2, 2012, to Discuss Top-Line Data Results From ... [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- Drug for rare disease may lift AVI BioPharma shares: Barron's [Last Updated On: April 2nd, 2012] [Originally Added On: April 2nd, 2012]
- AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 ... [Last Updated On: April 2nd, 2012] [Originally Added On: April 2nd, 2012]
- U.S. Stock Futures Little Changed Before Factory Report [Last Updated On: April 2nd, 2012] [Originally Added On: April 2nd, 2012]
- Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno [Last Updated On: April 20th, 2012] [Originally Added On: April 20th, 2012]
- Nature Publishes Work Utilizing N-Gene's Core Technology to Advance the Treatment of Duchenne Muscular Dystrophy [Last Updated On: April 20th, 2012] [Originally Added On: April 20th, 2012]
- Getting the boots filled [Last Updated On: April 29th, 2012] [Originally Added On: April 29th, 2012]
- Local business, civic leaders 'arrested' for MDA fundraiser [Last Updated On: May 3rd, 2012] [Originally Added On: May 3rd, 2012]